Literature DB >> 30644784

Identifying the barriers and perceptions of non-Hispanic black and Hispanic/Latino persons with uncontrolled type 2 diabetes for participation in a home Telemonitoring feasibility study: a quantitative analysis of those who declined participation, withdrew or were non-adherent.

Timothy Tong1, Alyson K Myers1,2,3, Aditya A Bissoonauth2,3, Renee Pekmezaris1,3,4, Andrzej Kozikowski5.   

Abstract

Objectives: Type 2 Diabetes Mellitus and its complications disproportionately affect non-Hispanic blacks and Hispanic/Latinos more than non-Hispanic whites. These disparities stem from complex interactions between biological, behavioral and socioeconomic factors. In recent years, telemedicine has been used to manage Type 2 Diabetes; however limited recruitment and retention of black and Hispanic/Latino patients into clinical trials exploring the use of telemedicine have necessitated the elucidation of their perceptions regarding participation in such trials. This study investigated patient-reported reasons for declining participation, prematurely terminating participation or demonstrating poor adherence to the study protocol in an ongoing randomized clinical trial, 'Feasibility of Telehealth Management of Diabetes Mellitus type 2 (T2DM) in Black and Hispanic Minority Patients'.Design: Semi-structured interviews comprised of open-ended questions and prompts were conducted by telephone to gauge patients' actual and perceived challenges to participating in the trial and using telemedicine to manage their diabetes. Data were collated with that of the original clinical trial and subsequently content analyzed for overarching themes and trends.
Results: Eight semi-structured interviews were completed telephonically. Themes that emerged from analysis included disinterest (47%), inconvenience (33%), lack of perceived benefit (13%), lack of awareness of diabetes diagnosis (7%) and perceived lack of ability to fully participate in the study (7%).
Conclusion: Adoption of telemedicine to help minority patients manage diabetes holds promise but is limited by patient factors such as disinterest, inconvenience and lack of perceived benefit. Greater awareness and understanding of these issues will be critical as we strive for greater health equity in disparity patients with uncontrolled diabetes.

Entities:  

Keywords:  Type 2 diabetes; barriers; diabetes; disparity; telemedicine

Year:  2019        PMID: 30644784     DOI: 10.1080/13557858.2019.1566520

Source DB:  PubMed          Journal:  Ethn Health        ISSN: 1355-7858            Impact factor:   2.772


  5 in total

1.  Telemedicine for Disparity Patients With Diabetes: The Feasibility of Utilizing Telehealth in the Management of Uncontrolled Type 2 Diabetes in Black and Hispanic Disparity Patients; A Pilot Study.

Authors:  Alyson Myers; Lubaina Presswala; Aditya Bissoonauth; Neha Gulati; Meng Zhang; Stephanie Izard; Andrzej Kozikowski; Kerry Meyers; Renee Pekmezaris
Journal:  J Diabetes Sci Technol       Date:  2020-08-29

Review 2.  The Use of Diabetes Technology to Address Inequity in Health Outcomes: Limitations and Opportunities.

Authors:  Shivani Agarwal; Iman Simmonds; Alyson K Myers
Journal:  Curr Diab Rep       Date:  2022-06-01       Impact factor: 5.430

3.  Expanded access to multiple sclerosis teleneurology care following the COVID-19 pandemic.

Authors:  Marisa P McGinley; Shauna Gales; William Rowles; Zhini Wang; Wan-Yu Hsu; Lilyana Amezcua; Riley Bove
Journal:  Mult Scler J Exp Transl Clin       Date:  2021-02-25

4.  Influence of Self-Practice Oriented Teaching plus Psychological Intervention on Blood Glucose Level and Psychological State in Patients with Type 2 Diabetes Mellitus on Insulin Therapy.

Authors:  Xuefang Li; Juan Ge; Lei He
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-08       Impact factor: 2.650

Review 5.  Inequity in Access and Delivery of Virtual Care Interventions: A Scoping Review.

Authors:  Sabuj Kanti Mistry; Miranda Shaw; Freya Raffan; George Johnson; Katelyn Perren; Saito Shoko; Ben Harris-Roxas; Fiona Haigh
Journal:  Int J Environ Res Public Health       Date:  2022-08-01       Impact factor: 4.614

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.